Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1983 1
1986 1
1988 1
1989 1
1990 4
1991 3
1992 2
1993 2
1994 2
1995 3
1996 5
1997 3
1998 2
1999 7
2001 4
2002 9
2003 8
2004 6
2005 8
2006 8
2007 4
2008 5
2009 12
2010 7
2011 9
2012 5
2013 10
2014 10
2015 5
2016 10
2017 14
2018 7
2019 13
2020 14
2021 23
2022 16
2023 19
2024 15
2025 13
2026 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

291 results

Results by year

Citations

2 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).
Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, Böckle BC, Caproni M, Caux F, Chandran NS, Cianchini G, Daneshpazhooh M, De D, Didona D, Di Zenzo GM, Dmochowski M, Drenovska K, Ehrchen J, Goebeler M, Groves R, Günther C, Horvath B, Hertl M, Hofmann S, Ioannides D, Itzlinger-Monshi B, Jedličková J, Kowalewski C, Kridin K, Lim YL, Marinovic B, Marzano AV, Mascaro JM, Meijer JM, Murrell D, Patsatsi K, Pincelli C, Prost C, Rappersberger K, Sárdy M, Setterfield J, Shahid M, Sprecher E, Tasanen K, Uzun S, Vassileva S, Vestergaard K, Vorobyev A, Vujic I, Wang G, Wozniak K, Yayli S, Zambruno G, Zillikens D, Schmidt E, Joly P. Borradori L, et al. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1689-1704. doi: 10.1111/jdv.18220. Epub 2022 Jun 29. J Eur Acad Dermatol Venereol. 2022. PMID: 35766904 Free article.
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. ...The degree of consent among all task force members was included. RESULTS: Treatment depends on the severity of BP and patien …
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membr …
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.
Karakioulaki M, Eyerich K, Patsatsi A. Karakioulaki M, et al. Am J Clin Dermatol. 2024 Mar;25(2):195-212. doi: 10.1007/s40257-023-00832-1. Epub 2023 Dec 29. Am J Clin Dermatol. 2024. PMID: 38157140 Free PMC article. Review.
Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. ...Neonatal Fc receptor antagonists such as efgartigimod are under investigation. Additionally, topical …
Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due …
Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, Kern JA, Lacouture ME. Geisler AN, et al. J Am Acad Dermatol. 2020 Nov;83(5):1255-1268. doi: 10.1016/j.jaad.2020.03.132. Epub 2020 May 23. J Am Acad Dermatol. 2020. PMID: 32454097 Free PMC article. Review.
Bullous pemphigoid eruptions, vitiligo-like skin hypopigmentation/depigmentation, and psoriasiform rash are more often attributed to programmed cell death-1/programmed cell death ligand-1 inhibitors. The treatment of bullous pemphigoid eruptions …
Bullous pemphigoid eruptions, vitiligo-like skin hypopigmentation/depigmentation, and psoriasiform rash are more often attribu …
Bullous pemphigoid.
Bağcı IS, Horváth ON, Ruzicka T, Sárdy M. Bağcı IS, et al. Autoimmun Rev. 2017 May;16(5):445-455. doi: 10.1016/j.autrev.2017.03.010. Epub 2017 Mar 8. Autoimmun Rev. 2017. PMID: 28286109 Review.
Bullous pemphigoid (BP) is the most common autoimmune bullous disorder which is characterized by autoantibodies against hemidesmosomal proteins of the skin and mucous membranes. ...Localised and mild BP can be treated with topical corticosteroids …
Bullous pemphigoid (BP) is the most common autoimmune bullous disorder which is characterized by autoantibodies against …
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
Murrell DF, Joly P, Werth VP, Ujiie H, Worm M, Mangold AR, Avetisova E, Maloney J, Laws E, Mortensen E, Dubost-Brama A, Shabbir A. Murrell DF, et al. Adv Ther. 2024 Jul;41(7):2991-3002. doi: 10.1007/s12325-024-02810-3. Epub 2024 Mar 5. Adv Ther. 2024. PMID: 38443648 Free PMC article.
BACKGROUND: Bullous pemphigoid (BP) is a rare, autoimmune, blistering skin disease associated with high disease burden, profoundly decreased quality of life and increased morbidity. ...Key secondary endpoints include total cumulative OCS dose to week 36, percent cha …
BACKGROUND: Bullous pemphigoid (BP) is a rare, autoimmune, blistering skin disease associated with high disease burden, profou …
Biological treatment for bullous pemphigoid.
Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A, Baum S. Oren-Shabtai M, et al. Front Immunol. 2023 Apr 27;14:1157250. doi: 10.3389/fimmu.2023.1157250. eCollection 2023. Front Immunol. 2023. PMID: 37180101 Free PMC article.
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease. Topical or systemic corticosteroids are often used as the first-line treatment. However, long-term corticosteroid use may lead to signi …
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease. Topical or syste …
Treatment of bullous pemphigoid.
Fontaine J, Joly P, Roujeau JC. Fontaine J, et al. J Dermatol. 2003 Feb;30(2):83-90. doi: 10.1111/j.1346-8138.2003.tb00353.x. J Dermatol. 2003. PMID: 12692373 Review.
Bullous pemphigoid (BP) is the most frequent auto-immune blistering skin disease. Up to recently, it was treated with oral corticosteroids. ...New strategies for BP should include topical clobetasol propionate as the first line treatment and con …
Bullous pemphigoid (BP) is the most frequent auto-immune blistering skin disease. Up to recently, it was treated with oral …
Dyshidrosiform Bullous Pemphigoid.
Cohen PR. Cohen PR. Medicina (Kaunas). 2021 Apr 20;57(4):398. doi: 10.3390/medicina57040398. Medicina (Kaunas). 2021. PMID: 33924249 Free PMC article. Review.
Dyshidrosiform bullous pemphigoid is a variant of bullous pemphigoid. At least 84 patients with dyshidrosiform bullous pemphigoid have been described. ...Similar to classic bullous pemphigoid, neurologic conditions and psych …
Dyshidrosiform bullous pemphigoid is a variant of bullous pemphigoid. At least 84 patients with dyshidrosiform …
Editor's Highlights-July 2026.
Kemény L. Kemény L. Int J Dermatol. 2026 Jul;65(7):1355-1356. doi: 10.1111/ijd.70518. Epub 2026 May 27. Int J Dermatol. 2026. PMID: 42204405
In this issue, we focus on two aspects of this evolving field: recent developments in the diagnostics of autoimmune blistering diseases and the clinical features of checkpoint inhibitor-associated autoimmune blistering diseases and their treatment options. These contributi …
In this issue, we focus on two aspects of this evolving field: recent developments in the diagnostics of autoimmune blistering diseases and …
291 results